Scholarly Index
Martha Grogan
Mayo Clinic; 21,307 total citations; 298 total publications; best world rank #21
Mayo Clinic
21,307Total citations
298Total publications
64H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 70 | US 43 | 98.84 |
| Parathyroid Disorders and Treatments | Lifetime | 177 | US 92 | 98.74 |
| Peptidase Inhibition and Analysis | Lifetime | 545 | US 253 | 98.11 |
| Eosinophilic Disorders and Syndromes | Lifetime | 293 | US 142 | 97.71 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 481 | US 171 | 94.04 |
| Dermatological and Skeletal Disorders | Lifetime | 710 | US 245 | 88.71 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 21 | US 10 | 99.03 |
| Parathyroid Disorders and Treatments | 2021-2025 | 45 | US 14 | 97.69 |
| Peptidase Inhibition and Analysis | 2021-2025 | 117 | US 33 | 97.11 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 124 | US 65 | 94.61 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 232 | US 78 | 89.13 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 570 | US 143 | 83.62 |
| Dermatological and Skeletal Disorders | 2021-2025 | 111 | US 33 | 81.15 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 391 | US 176 | 61.27 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 685 | US 109 | 48.52 |